Valued at a market cap of $28 billion, Humana Inc. (HUM) is a leading U.S. health care plan provider offering medical and specialty insurance products. Operating through its Insurance and CenterWell segments, the company delivers a wide range of services including Medicare, Medicaid, pharmacy benefits, home health, and senior-focused care.

The Louisville, Kentucky-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Wednesday, Jul. 30. Ahead of the event, analysts forecast Humana to report an adjusted EPS of $6.32, down 9.2% from $6.96 in the year-ago quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. 

For fiscal 2025, analysts project the health insurer to report adjusted EPS of $16.38, up 1.1% from $16.21 in fiscal 2024. 

Shares of Humana have decreased 38.8% over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 11.5% rise and the Health Care Select Sector SPDR Fund's (XLV) 6.8% decline over the same period.

Despite reporting weaker-than-expected Q1 2025 revenue of $32.1 billion, Humana's shares rose 1.1% on Apr. 30 due to its strong adjusted EPS of $11.58, which beat estimates and surged 60.2% year-over-year. Investors were also encouraged by a 190 bps improvement in the benefit ratio to 87% and a 74.8% jump in Insurance segment operating income, reflecting strong Medicare Advantage pricing and growth in PDP and state-based contract businesses. Additionally, robust CenterWell performance, with a 5.7% revenue increase and 34.6% rise in operating income, further supported positive investor sentiment.

Analysts' consensus rating on Humana stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 22 analysts covering the stock, six recommend a "Strong Buy,” two have a "Moderate Buy," and 14 give a "Hold" rating. As of writing, the stock is trading below the average analyst price target of $289.05.